We observed that KRAS mutations frequently occur in PAAD, COAD, READ, LUAD, etc. Moreover, KRAS mutations are significantly correlated with the KRAS levels in tumor cohorts, suggesting that KRAS expression is associated with the oncogenic roles. Here, KRAS is linked to pancreatic adenocarcinoma.